Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (gastric chief cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: tg100-801, xl-228, ilorasertib +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 1,244 | 0.74 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14549
Sealed predictions
- SRMS in dopamine neurons, braak-0.49 (p 0.177) → -0.57 (p 0.108)receipt 14556
Swarm cases
receipt 14556: SRMS in dopamine neurons, braak
- power
- full sample -0.42 (p 0.080, n 18), 95% CI -0.74 to +0.05. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.089, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.015, n 18). not the mix.
- skeptic
- leave-one-out range -0.57 to -0.35, sign flips 0; without severely affected donors -0.42 (p 0.080, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SRMS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts